ClinicalTrials.gg
CompletedNCT02165033Updated Jun 3, 2015

Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers

A Phase 1 interventional study of Budesonide/Procaterol 180/10 X 4 puffs in Asthma, sponsored by Intech Biopharm Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-03.

Sponsored by Intech Biopharm Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 88 studies in Asthma with a site in Taiwan — 13 open to participants now, 18 under way, 4 of them phase 3. Asthma · Taiwan.

Enrollment
72nd of 72
16 · median 274
Started
2012
with 2 others
Phase 1
6 of 88
none open now
Registered
26th of 88
by date
Lead sponsor
7 of 88
Intech Biopharm Ltd.

Among the 88 studies in Asthma with a site in Taiwan, this one is the 72nd largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2012, is one of 6 in phase 1, and was the 26th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

13 of the 88 studies in Asthma with a site in Taiwan are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Asthma with a site in Taiwan, or all of them as a file.
02

Study summary

Budesonide + Procaterol HFA MDI is a novel asthma product containing both budesonide and procaterol in a single inhaler. Budesonide is a corticosteroid that treats underlying airway inflammation in asthma. Procaterol is a direct acting sympathomimetic with predominantly Beta-adrenoceptor stimulant activity selective to Beta-2 receptors (a Beta-2 agonist). It is used as a bronchodilator in the management of reversible airways obstructive pulmonary disease. Budesonide and Procaterol therefore have complementary effects, treating two different components of asthma.

Read the detailed description

Test drug: SYN006 HFA MDI Batch No: BPP-033-088 Dosage Form: HFA Metered Dose Inhaler Active Substance: Budesonide 180ug and procaterol hydrochloride hydrate 10ug/dose Dosage regimen: Multiple dose (4 puffs: budesonide 720ug and procaterol hydrochloride hydrate 40ug); thirteen consecutive doses

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed written before enrollment into the study, ability to communicate with the investigators, and to understand and comply with the requirements of the study.
  • Healthy adults, aged between 20 and 40 years old.
  • Subjects with (BMI) of >=18.5 and \<=25.0 (BMI will be calculated as weight in kilogram [kg]/height in meters2 [m2]).
  • Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, chest x-ray and .
  • Clinical laboratory test: within limit of normal range or acceptable to investigator.

Exclusion criteria

Exclusion Criteria:

  • History of drug or alcohol abuse within the past year.
  • Medical history of severe drug allergy or sensitivity to analogous drug.
  • Evidence of acute or chronic diseases or having undergone surgery from 4 weeks prior to Period I dosing.
  • Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal pathology. Creatinine > 2UNL (upper normal limit); Liver enzymes > 2UNL; Total > 2UNL.
  • Planned vaccination during the time course of the study.
  • Taking any clinical investigation drug from 2 months prior to Period I dosing.
  • Use of any medication, including herb medicine from 4 weeks before dosing.
  • Donation of 500mL of blood in the past 3 months prior to dosing or donation of 250mL of blood in the past 2 months prior to dosing.
  • A positive surface antigen or positive antibody result.
  • A positive test for antibody.
  • In screening subjects will be given training to ensure that subjects are able to correctly use the products. If the subjects, the use of the investigational products lack of proficiency will not be included in this study.
  • Students of National Defense Medical Center.
  • For female subjects, if they meet any of the following criteria:

    1. Lactating women
    2. Positive pregnancy test (urine) at screening, or prior to dosing
    3. Do not use adequate during the study
    4. Women taking oral contraceptives
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Budesonide/Procaterol 180/10 X 4 puffs

    Multiple dose of SYN006 HFA MDI (Budesonide 180ug + Procaterol 10ug/puff), 4 puffs each day for consecutive 7 days

    Drug: Budesonide/Procaterol 180/10 X 4 puffs

Interventions

  • DrugBudesonide/Procaterol 180/10 X 4 puffs

    Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose

    Also known as: SYN006 HFA MDI

06

What researchers measure

Primary outcomes

  1. Area Under Curve (AUC) at day 1

    Time frame: predose,0.083,0.167,0.333,0.5,0.75,1,1.5,2,3,4,6,8,10,12 hours post-dose

  2. Peak Plasma Concentration (Cmax) at day 1

    Time frame: predose,0.083,0.167,0.333,0.5,0.75,1,1.5,2,3,4,6,8,10,12 hours post-dose

  3. Tmax at day 1

    Time frame: predose,0.083,0.167,0.333,0.5,0.75,1,1.5,2,3,4,6,8,10,12 hours post-dose

  4. Area Under Curve (AUC) at day 7

    Time frame: predose,0.083,0.167,0.333,0.5,0.75,1,1.5,2,3,4,6,8,10,12 hours post-dose

  5. Peak Plasma Concentration (Cmax) at day 7

    Time frame: predose,0.083,0.167,0.333,0.5,0.75,1,1.5,2,3,4,6,8,10,12 hours post-dose

  6. Tmax at day 7

    Time frame: predose,0.083,0.167,0.333,0.5,0.75,1,1.5,2,3,4,6,8,10,12 hours post-dose

Secondary outcomes

  1. Accumulation ratio of AUC at day 1 and day 7

    Time frame: 0.083, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose

07

Study locations

1 site
  • Tri-Service General Hospital
    Taipei, Neihu 114, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jan 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2014
First posted
Jun 17, 2014
Start
Nov 2012
Primary completionActual
Jan 2013
CompletionActual
Feb 2013
Last update
Jun 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02165033
Lead sponsor
Intech Biopharm Ltd.
Responsible party
Sponsor
First posted
Jun 17, 2014
Start date
Nov 2012
Primary completion
Jan 2013
Completion
Feb 2013
Last update
Jun 3, 2015

Study contacts

C W Perng, M.D
principal investigator · Tri-Service General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion